The long period of time when the stock languished below 6c after the CR, was a great opportunity to average down. Hopefully many were able to do so, confronting the abyss of Investor despair.
Now in the green, l am happy to wait for the clinical trials to take their course and to back the research teams ongoing R&D.
This is an early stage recovery stock in my view. I expect volatility will continue between 10c to 12c until the price breaks out of that range. The catalyst would have to be a positive announcement, which if course cannot be guaranteed to come.
That uncertainty is the risk one takes of a bird in the hand or a flock of birds in a bush. This is a multi bag stock IMO, so l am betting on the flock.
